Literature DB >> 1740492

Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.

S Ulick1, R Tedde, J Z Wang.   

Abstract

Impaired peripheral metabolism of cortisol in the syndrome of apparent mineralocorticoid excess is currently understood to be causally related to the severe but otherwise unexplained manifestations of mineralocorticoid excess. A normally ambivalent mineralocorticoid receptor responding equally well to glucocorticoids and mineralocorticoids requires prereceptor inactivation of glucocorticoids to elicit a specific mineralocorticoid effect. The failed inactivation step in the form of the syndrome of apparent mineralocorticoid excess first described (type 1) involves the 11 beta-hydroxydehydrogenation of cortisol to cortisone. In another form of the syndrome (type 2) this conversion occurs normally in the face of otherwise similar clinical and biochemical features. Markedly decreased cortisol metabolic clearance in the type 2 form suggested impairment of a major component of that clearance, ring A reduction. A noninvasive method was developed for measuring the conversion of cortisol to tetrahydrocortisol and allotetrahydrocortisol, and this step was found to be profoundly decreased in both type 1 and type 2 forms. Thus, the major abnormality in the peripheral metabolism of cortisol common to both forms involved ring A reduction, not 11 beta-hydroxydehydrogenation. Since ring A reduction was better correlated with the manifestation of mineralocorticoid excess in both forms of the syndrome, this step might also be a normal major prereceptor mechanism conferring mineralocorticoid specificity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1740492     DOI: 10.1210/jcem.74.3.1740492

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

Authors:  R Tedde; A Pala; A Melis; S Ulick
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

3.  Clinical quiz. Differential diagnosis of a patient with hypertension.

Authors:  R Holleman; E D Avner
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

4.  Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.

Authors:  M Palermo; G Delitala; F Mantero; P M Stewart; C H Shackleton
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

5.  Intense physical exercise increases systemic 11beta-hydroxysteroid dehydrogenase type 1 activity in healthy adult subjects.

Authors:  Andrea Dovio; Eliana Roveda; Chiara Sciolla; Angela Montaruli; Andrea Raffaelli; Alessandro Saba; Giovanna Calogiuri; Silvia De Francia; Paolo Borrione; Piero Salvadori; Franca Carandente; Alberto Angeli
Journal:  Eur J Appl Physiol       Date:  2009-11-10       Impact factor: 3.078

6.  Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: overt and subclinical hypothyroidism.

Authors:  M C Vantyghem; A Ghulam; C Hober; C Schoonberg; M D'Herbomez; A Racadot; A Boersma; J Lefebvre
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

7.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

8.  Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.

Authors:  A Gambineri; G Forlani; A Munarini; F Tomassoni; G E Cognigni; W Ciampaglia; U Pagotto; B R Walker; R Pasquali
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

Review 9.  Novel methods in adrenal research: a metabolomics approach.

Authors:  Thomas G Papathomas; Na Sun; Vasileios Chortis; Angela E Taylor; Wiebke Arlt; Susan Richter; Graeme Eisenhofer; Gerard Ruiz-Babot; Leonardo Guasti; Axel Karl Walch
Journal:  Histochem Cell Biol       Date:  2019-02-06       Impact factor: 4.304

10.  Reduced cortisol metabolism during critical illness.

Authors:  Eva Boonen; Hilke Vervenne; Philippe Meersseman; Ruth Andrew; Leen Mortier; Peter E Declercq; Yoo-Mee Vanwijngaerden; Isabel Spriet; Pieter J Wouters; Sarah Vander Perre; Lies Langouche; Ilse Vanhorebeek; Brian R Walker; Greet Van den Berghe
Journal:  N Engl J Med       Date:  2013-03-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.